Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Leases (2020 - 2025)

Historic Current Leases for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Barinthus Biotherapeutics' Current Leases rose 156.09% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 156.09%. This contributed to the annual value of $1.9 million for FY2024, which is 756.3% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Current Leases stood at $2.0 million, which was up 156.09% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Current Leases ranged from a high of $2.0 million in Q2 2025 and a low of $186000.0 during Q3 2022
  • Over the past 5 years, Barinthus Biotherapeutics' median Current Leases value was $1.1 million (recorded in 2023), while the average stood at $1.1 million.
  • In the last 5 years, Barinthus Biotherapeutics' Current Leases crashed by 5724.14% in 2022 and then skyrocketed by 70698.92% in 2023.
  • Over the past 5 years, Barinthus Biotherapeutics' Current Leases (Quarter) stood at $523000.0 in 2021, then decreased by 17.21% to $433000.0 in 2022, then surged by 312.24% to $1.8 million in 2023, then increased by 7.56% to $1.9 million in 2024, then grew by 5.05% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $2.0 million during Q1 2025.